Steven Gourlay

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.

GBS Venture Partners Pty Ltd (GBS Venture Partners) is a venture capital firm founded in 1996 by Helen Brigitte Smith and Geoff E.D Brooke. The firm is headquartered in Melbourne.

Applied Physiology developed and commercializes guidance devices for use in the critical care environment. Navigator™, the flagship product, focuses on hemodynamic management. Applied Physiology aims to develop products that make life easier for the clinician. The devices continuously acquire physiological data from conventional monitors and use it to create a graphical depiction of the patient position, and continuous advice on the next therapy. Applied Physiology's devices enable the implementation of targeted therapy to optimize care and outcomes. The clinician specifies target ranges for the variables being monitored. The devices graphically display the patient position in relation to these targets, and indicate a course of therapy that will guide the patient to the target area. This self-adaptive protocol facilitates a safe and systematic approach to bedside care, where whole teams work toward a unified goal. Applied Physiology's therapeutic guidance devices have demonstrated potential benefits for both clinicians and patients: Clinical teamwork is enhanced and goals unified, Improved patient put comes, Reduced length of stay and Reduced morbidity in critical care units. At the heart of Applied Physiology's technology are mathematical algorithms based on a combination of systems physiology and control engineering methods. This rigorous basis has enabled the development of sound and reliable patient-specific solutions to treatment planning problems that are often counter-intuitive. Applied Physiology's flagship product Navigator™, which targets pressure and flow in the circulatory system, will be available for sale in Europe and Australia in the second quarter 2010. It will be available for sale in the U.S. pending regulatory approval from the FDA. The company is based Australia, and established European operations in the UK in 2008.

Verva Pharmaceuticals Ltd. developed therapies to treat diabetes. Its products include insulin sensitizers, insulin secretagogues, fat formation inhibitors for the prevention, treament of obesity, drug-induced weight gain and insulin secretion modulators. The company was founded in 1996 and was headquartered in Geelong, Australia.

Elastagen Pty Ltd. produces and develops synthetic human elastin for medical device applications. Its products include skin rejuvenation, scar remodeling, skin tissue repair, wound healing, surgical glues and sealants. The firm developed a Elastatherapy treatments which offer the chance to restore the levels of Elastin in human skin, with benefits anticipated in both medical dermatology and cosmetic applications. The company was founded by Anthony Weiss in 2003 and is headquartered in Sydney, Australia.

Endoluminal Sciences Pty Ltd. develops novel platform technologies for endovascular prostheses. The firm’s focus is to develop the treatment of abdominal aortic aneurysms (AAAs). The company was founded by Ashish Mitra and Martin Ng in 2007 and is headquartered in Sydney, Australia.